Founded

Address

Other Office
485 Ramona Street
Palo Alto, CA 94301
United States

Open map


Recent investment activity

KANDO id: 28400

Corporate information

Also known as
ATV Capital
Registration country

Company type

Venture capital firm with a focus on Information Technology, Healthcare and Cleantech

Funding rounds

Investment preferences

Industry focus comment
IT, Healthcare, Clean Technology, Biotechnology
Stage focus summary
All stages
Top investment portfolio themes
robotics (1)  

Actual initial investment stage
N/A (3)

Investment activity status
Active investor

Selected investments

Displaying 76 - 100 of 106
Profile Country Date Funding
Acceleron Pharma Inc Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. Series A Initial investment
Accord Networks Ltd N/A
Acme Packet Inc N/A
Actel Corp N/A
ActiFio Inc Provider of data management virtualization solutions to simplify data protection, disaster recovery, and business continuity. Venture
ActiFio Inc Provider of data management virtualization solutions to simplify data protection, disaster recovery, and business continuity. N/A
Alfalight Inc Designer and manufacturer of high-power diode lasers for the industrial, defense and telecommunications markets. N/A
AltaRock Energy Inc N/A
Altura Medical Inc Series A
Anagran Inc Series D
Anagran Inc Series C
Anagran Inc Series B
Annuncio Software Inc Online personalization software company. N/A Initial investment
Aperio Technologies Inc N/A
Aquion Energy Inc N/A
Ardian Inc Medical device company that develops catheter-based therapies to treat hypertension and related conditions. Series C Initial investment
ChannelAdvisor Corp N/A Initial investment
EndoGastric Solutions Inc Series F
EndoGastric Solutions Inc Series E
EndoGastric Solutions Inc Venture
EndoGastric Solutions Inc Series B
EndoGastric Solutions Inc Series A
Garage Technology Ventures LLC N/A
GluMetrics Inc N/A
Holaira Inc Developer of minimally-invasive products to make breathing easier for patients suffering from obstructive lung diseases Series C

Current team

Past employees

Selected Products / Customers

Financials